

CURRICULUM VITAE

JOHN C. MORRIS, M.D.**DATE:** May 2005**DATE OF BIRTH:** ---**PLACE OF BIRTH:** ---**CITIZENSHIP:** ---

ADDRESS & TELEPHONE: Office: Department of Neurology
 Campus Box 8111-ADRC
 Washington University School of Medicine
 660 South Euclid Avenue
 St. Louis, MO 63110
 (314) 286-2683 (FAX: 314-286-2448)

Home: ---

PRESENT POSITION: Harvey A. & Dorismae Hacker Friedman Distinguished Professor of Neurology;
 Professor of Pathology and Immunology;
 Professor of Physical Therapy
 Director, Alzheimer's Disease Research Center;
 Director, Memory and Aging Project;
 Director, Memory Diagnostic Center;
 Director, Center for Aging;
 Washington University School of Medicine

EDUCATION:

B.A., Ohio Wesleyan University, Delaware, Ohio

M.D., University of Rochester School of Medicine and
 Dentistry, Rochester, New York**TRAINING:**

Intern, Rotating-1, San Francisco General Hospital, San Francisco,
 California

Assistant Resident and Senior Resident in Medicine, Akron General
 Medical Center, Akron, Ohio

Assistant Resident and Senior Resident (Chief Resident) in Neurology,
 Cleveland Metropolitan General Hospital, Cleveland, Ohio

Resident in Neuropathology, Cleveland Metropolitan General Hospital,
 Cleveland, Ohio

Postdoctoral Fellow in Neuropharmacology, Department of Pharmacology.
National Institute of Neurological Disorders and Stroke Training Grant
NS07129. Washington University School of Medicine, St. Louis, MO

**UNIVERSITY
APPOINTMENTS:**

July 1981-June 1982	Demonstrator in Neuropathology, Case Western Reserve University School of Medicine, Cleveland, Ohio
July 1982-June 1984	Research Instructor in Pharmacology, Washington University School of Medicine, St. Louis, Missouri
July 1983-June 1985	Instructor in Neurology, Washington University School of Medicine, St. Louis, Missouri
July 1985-June 1991	Assistant Professor of Neurology, Washington University School of Medicine, St. Louis, Missouri
March 1989-2000	Assistant Professor of Pathology and Immunology (Neuropathology), Washington University School of Medicine, St. Louis, Missouri
July 1991-December 1997	Associate Professor of Neurology, Washington University School of Medicine, St. Louis, Missouri
January 1998-Present	Professor of Neurology, Washington University School of Medicine, St. Louis, Missouri
January 2001-Present	Professor of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
January 2002-Present	Member of Search Committee, Neurology Department Chair, Washington University School of Medicine, St. Louis, Missouri
January 2003-Present	Member of Board of Directors, Faculty Practice Plan, Washington University School of Medicine, St. Louis, Missouri
January 2003-Present	Professor of Physical Therapy Washington University School of Medicine, St. Louis, Missouri
2004-Present	Member, Radiology Appointments/Promotions Ad Hoc Committee, Washington University School of Medicine, St. Louis, Missouri

**HOSPITAL
APPOINTMENTS:**

July 1975-August 1976	Fairbanks General Hospital, Fairbanks, Alaska
November 1976-June 1977	Carlsbad Regional Medical Center, Carlsbad, New Mexico
1984-Present	Barnes-Jewish Hospital, St. Louis, Missouri
1984-1997	St. Louis Regional Medical Center, St. Louis, Missouri
1988-1994	Associate Neurologist-in-Chief, Jewish Hospital, St. Louis, Missouri
1989-Present	Director, Memory Diagnostic Center, Barnes-Jewish Hospital, St. Louis, Missouri

LICENSURE:

Missouri

CERTIFICATION:

National Board of Medical Examiners

American Board of Internal Medicine

American Board of Psychiatry and Neurology (Neurology)

HONORS

Board of Directors, Alzheimer Association, Chicago, IL
 Distinguished Achievement Citation, Ohio Wesleyan University (May 2000)
 Who's Who in the World
 Who's Who in America
 Castle Connolly Top Doctors in America (2001-2004)
 America's Top Physicians (2003)
 Chair, American Association of Neurology Section on Geriatric Neurology (2004-2006)
 Consultant, Dept of Health and Human Services, Public Health Service, Medical and Immunology Devices Committees, Food and Drug Administration (2004-present)
 Alzheimer's Association Lifetime Achievement Award (2004)
 2004 MetLife Foundation Award for Medical Research in Alzheimer's Disease
 2005 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology

EDITORIAL BOARDS

1992 - Present

The Neurologist

1994 - Present

Alzheimer's Disease and Associated Disorders: An International Journal
(Editor-in-Chief, 2001 – Present)

2000 – Present

Marcel Dekker, Advisory Board for Neurological Disease and Therapy series

Ad hoc reviewer for:

The American Journal of Medicine, Annals of Neurology, Archives of Internal Medicine, Archives of Neurology, Biological Psychiatry, Brain, International Psychogeriatrics, Journal of the American Geriatrics Society, Journal of the American Medical Association, Journal of Gerontology, Journal Watch Neurology, The Lancet, Nature, Neurology, Mayo Clinic Proceedings, Neurology Network Commentary, Neurobiology of Aging, Neuroscience Letters, Science, Journal of Neuroscience, Lancet Neurology.

SCIENTIFIC and COMMUNITY**ADVISORY BOARDS**

1986 - 1997

Director, CERAD Clinical Task Force (Consortium to Establish A Registry for Alzheimer's Disease)

1986 - Present

St. Louis Chapter of the Alzheimer's Association

1990 – Present

Internal Ethics Committee, Alzheimer's Disease Cooperative Study

1995 - 1997

State of Missouri Alzheimer's Disease and Related Disorders Program

1995 - 1998

International Scientific Committee, Fifth and Sixth International Conferences on Alzheimer's Disease and Related Disorders

1996

International Scientific Advisory Committee, Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

1996 - Present

International Research Advisory Board, World Health Organization on the Development of Methodologies for Early Diagnosis, Prevention, and Treatment of Alzheimer's Disease

1998 - Present

Medical/Vision Advisory Board, State of Missouri (for impaired drivers)

1998 - Present

Member, Board of Directors, Alzheimer Association, Chicago, IL

1999 - Present	Program Committee, World Alzheimer Congress 2000
1999 -	Alzheimer Association's Work Group on National Research Priorities
1999 -	Alzheimer Association's Work Group on Interventions for Alzheimer Disease
2000 -	Alzheimer Association's Work Group on Screening for Cognitive Impairment and Alzheimer Disease
2001 -	Alzheimer Association's Work Group on Imaging
2002 -	Alzheimer Association's Work Group on Economics of Imaging
2000 - Present	Member, Scientific Advisory Board, Institute for the Study of Aging, Inc.
2001 - Present	Board of Directors, Jewish Center for the Aged (St. Louis)
2002 -	Member, Advisory Board, Alzheimer Research Forum
2002 -	Member, Older Drivers Project of the American Medical Association
2003-	Member, Medical Advisory Council, Association for Frontotemporal Dementias, Philadelphia, PA.
2005-	Leeza Gibbons Memory Foundation Scientific Advisory Board
2005-	Medical and Scientific Advisory Council of the Alzheimer's Association

Alzheimer Disease Center and Dementia Programs Advisory Boards

1994 - 1997	Executive Committee, National Institute on Aging Alzheimer's Disease Center Directors (Chair, 1996 – 1997)
1994 - Present	Johns Hopkins University Alzheimer's Disease Research Center
1995 - Present	University of Michigan Alzheimer's Disease Research Center
1997 - Present	University of Texas, Southwestern Medical School Alzheimer Disease Center
1998 - Present	Case Western Reserve University Alzheimer Disease Center
1998 - Present	University of Alabama, Birmingham Alzheimer's Disease Center
1998 - Present	Boston University/Bedford VAMC Alzheimer's Disease Center
2000 - Present	Mayo Clinic Alzheimer's Disease Research Center
2001 - Present	University of Arkansas Medical Sciences Alzheimer Disease Center
2002 - Present	University of Pennsylvania Alzheimer Disease Center
2002 - Present	Utah State University in Logan, Cache County
2003 -	Chair, External Advisory Committee meeting for University of California, San Francisco, program project grant on Frontotemporal Dementia, San Francisco

REVIEW COMMITTEES

1996 - 2000	National Institute on Aging: Neuroscience of Aging Review Committee (NIA-N), (Chair 1999-2000)
Ad hoc:	National Institute on Aging; National Institute of Neurological Disease and Stroke; National Heart, Lung, and Blood Institute State of California Department of Health Services Veterans Administration Alzheimer Association Medical Research Council The Memory Ride Grant For Multidisciplinary Research in Alzheimer's Disease

PROFESSIONAL SOCIETIES AND ORGANIZATIONS:

American College of Physicians; (**Fellow - 1989**)
 American Academy of Neurology; (**Fellow - 1993**)
 Chair, Clinical Practice Committee and member,
 Executive Committee, Geriatric Neurology Section
 Member, Commission on Subspecialty Certification
 American Neurological Association
 American Geriatrics Society

Central Society for Neurological Research (**President, 1995-1996**)
 Society for Neuroscience
 Society for Experimental Neuropathology
 Missouri State Neurological Association
 American Society for Experimental NeuroTherapeutics
 International College of Geriatric Psychoneuropharmacology
 Research Group on Dementia (**Executive Committee 2001-present**)
 World Federation of Neurology
 Asia-Pacific International Working Group on Harmonization of Dementia
 Drug Guidelines (**Executive Committee 2001-present**)

INVITED LECTURESHIPS SINCE 1999 (Selected)

1. January 4, 1999. "Frontotemporal dementias: phenotypes and genotypes", Washington University School of Medicine, Department of Neurology/Neurosurgery Research Seminar.
2. January 12, 1999. "Early detection and management of Alzheimer's disease," Grand Rounds, Neuropsychiatric Institute, University of Utah.
3. February 18, 1999. "Mild Cognitive Impairment Simply Incipient Alzheimer's Disease?". Cognitive Neurology and Alzheimer Disease Center Seminar Series; Northwestern University Medical School.
4. February 23, 1999. "Mild Cognitive Impairment" Winter Conference on Neural Plasticity, St. Lucia, West Indies.
5. March 12, 1999. "Is mild cognitive impairment simply incipient Alzheimer's disease?", Grand Rounds, Barrow Neurological Institute, Phoenix, AZ.
6. March 25, 1999. "Medical Overview" St. Louis Chapter of the Alzheimer Association, St. Louis, MO.
7. May 6, 1999. "Senility and Alzheimer's disease: Are they the same?" Scientific Program, Washington University Medical Alumni Reunion '99.
8. May 12, 1999. "Clinical assessment of dementia", Academy of Medicine, Singapore.
9. May 13, 1999. Plenary Lecture: "Ethical issues in dementia management and research", 2nd Asia Pacific Interscience Congress of Medicine, Singapore.
10. May 16, 1999. "The pre-Alzheimer condition", American Psychiatric Association Annual Meeting, Washington D.C.
11. May 18, 1999. "Scales used to assess cognition", American Psychiatric Association Annual Meeting, Washington, D.C.
12. May 21, 1999. "Treatment of Alzheimer disease: Clinical trials and endpoint evaluation", AGS/AFAR Annual Meeting, Philadelphia, PA.
13. June 24-30, 1999. Lecturer, "Molecular mechanisms of human neurological diseases", Cold Spring Harbor Laboratory summer course, Cold Spring Harbor, New York, NY.
14. August 16, 1999. "Early identification of the Alzheimer patient", Ninth Congress of the International Psychogeriatric Association, Vancouver, Canada.
15. October 5, 1999. "Alzheimer's disease", Medical Grand Rounds, St. Luke's Hospital, St. Louis, MO.

16. November 13, 1999. Moderator, "Alzheimer Research Update", Missouri Alzheimer Coalition and St. Louis Chapter of the Alzheimer Association, University of Missouri, St. Louis, MO.
17. November 16, 1999. Symposium Chair, "Mild cognitive impairment as a target for therapeutic intervention", 4th Annual Conference on the Therapeutics of Alzheimer's Disease, Mount Sinai Medical Center, New York, NY.
18. December 1, 1999. "Preclinical Alzheimer's disease", Conjoint Neurological Conference, Washington University, St. Louis, MO.
19. December 18, 1999. "New treatments for Alzheimer's disease", 1st International Clinical Neuroscience Symposium, Punta del Este, Uruguay.
20. February 1, 2000. Discussant, "Memory impairment in humans", 9th Adler Symposium on Alzheimer's Disease, The Salk Institute, La Jolla, CA.
21. February 17, 2000. "Differential diagnosis of dementias," Biomarkers for Alzheimer's Disease Workshop, Roche Pharmaceuticals, Basel, Switzerland.
22. April 8-14, 2000. "Lessons from clinicopathologic studies of healthy aging and very mild Alzheimer's disease," 6th Conference of Neurodegenerative Disorders, Tobago, West Indies.
23. April 29 – May 5, 2000, 52nd Annual Meeting, American Academy of Neurology, San Diego, CA. Alzheimer's disease can be diagnosed during life" 1KP.012, Controversies in Alzheimer's disease Current therapy available for Alzheimer's disease" 5TP.001, Dementia Therapy "Is mild cognitive impairment simply incipient Alzheimer's disease?" 7BS.002, Course Director "Alzheimer's disease" 7AS.001, case studies in Alzheimer's disease
24. May 25-26, 2000. "Is Alzheimer's a disease or exaggerated aging?" UCSD Alzheimer's Disease Research Center Annual Conference, San Diego, CA..
25. July 8, 2000. "Mild cognitive impairment: An early stage of AD?" CME approved satellite symposium, Alzheimer's disease: Translating neurochemical insight into clinical benefits. World Alzheimer Congress, Washington, DC.
26. July 11-13, 2000. World Alzheimer Congress, Washington, DC.

: "Imaging and Memory Disorders." Co-chaired the WAC session (Code C-6).

: "Healthy brain aging in nonagenarians and centenarians", "Functions and structure of the aged brain". Presented at WAC session.

: "How to use cholinergic treatments to achieve optimal benefits." Janssen-sponsored Roundtable Meeting on "Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success?" Moderated discussion on "How to use cholinergic treatments to achieve optimal benefits".

27. July 21-27, 2000. "Clinico-pathological correlations in cognitive impairment & Alzheimer's disease." Molecular Mechanisms of Human Neurological Diseases, Cold Spring Harbor Laboratory, Harbor, NY.
28. October 27-28, 2000. "From foundations to the future: Commencing a new era in the management of Alzheimer's disease." Co-chaired the Janssen-sponsored International Symposium, Seville, Spain.

29. November 10-11, 2000. "Advances in the treatment of Alzheimer's", "History of Alzheimer's disease research: A satellite broadcast program, Alzheimer's disease: Bridging Research and Care. Alzheimer's Association, St. Louis Chapter, St. Louis, MO.
30. November 14, 2000. "Is Alzheimer's Inevitable if we simply live long enough?" Alzheimer Association, Greater Dallas Chapter, Richard J. Price Conference on "Alzheimer's Disease: Help for Today, Hope for Tomorrow", Dallas, TX.
31. November 17, 2000. "Detecting and treating early Alzheimer's disease". Alzheimer Association, 9th Annual Symposium, "A World Without Alzheimer's", Dayton, OH.
32. December 8-10, 2000. "Is Alzheimer's disease inevitable with age?" 2nd Conference on Longitudinal Studies in Aging and Alzheimer's disease. University of Kentucky ADRC, Lexington, KY.
33. February 21, 2001. "Alzheimer's disease: Who will develop it as we live longer?" Science seminar, held at the Anheuser Busch Hall of the Living World at the St. Louis Zoo, St. Louis, MO.
34. March 9, 2001. "Mild cognitive impairment: Clinical update and pathologic correlates". Symposium sponsored by the American Health Assistance Foundation - Recent Advances in Alzheimer's disease research held in San Mateo, CA.
35. April 14, 2001. "Mild cognitive impairment: Clinical update and pathologic correlates". Symposium of the Japan Academy of Alzheimer Disease, Keidanren Conference Center, Tokyo, Japan.
36. May 4, 2001. "Update on Alzheimer's and Dementia", Northeast Ohio University College of Medicine (NEOUCOM) at Sheraton Suites, Cuyahoga Falls, OH.
37. May 6, 2001. "Final Answer II" – dementia session, American Academy of Neurology (AAN) education course, Philadelphia, PA.
38. May 10, 2001. "Alzheimer Therapy", American Academy of Neurology (AAN) education course, Philadelphia, PA.
39. May 11, 2001. "Is MCI simply early-stage Alzheimer's disease", American Academy of Neurology (AAN) breakfast seminar, Philadelphia, PA.
40. June 15, 2001. "Early diagnosis and treatment of Alzheimer's disease", Second Jim Flood Memorial Lecture at the 12th annual St. Louis University Summer Geriatric Institute. St. Louis, MO.
41. July 11, 2001. "New advances in Alzheimer's disease", Grand Rounds presented for the Department of Psychiatry and Neurology, University of Missouri School of Medicine, Columbia, MO.
42. September 7, 2001. "Is dementia inevitable with age?", Fall Address for the Lifelong Learning Institute of the University College of Washington University.
43. October 2, 2001. "Is MCI simply early-stage Alzheimer Disease?" Turken Lectureship, University of California, Los Angeles.
44. October 17, 2001. "Early diagnosis and treatment of Alzheimer disease". Grand Rounds for Division of Geriatric Medicine, Department of Internal Medicine, St. Louis University Medical School.
45. November 7, 2001. "Is mild cognitive impairment actually the beginning of Alzheimer's disease?". 15th Annual Joseph M. Foley, MD, Lectureship in Cleveland, Ohio for the Cleveland Area Alzheimer Association.

46. November 12, 2001. "Brain aging and Alzheimer's: Same or Different?". 2001 Sagan National Colloquium, Ohio Wesleyan University, Delaware, Ohio.
47. November 13, 2001. "Alzheimer's Research : Past, Present, and Future". Keynote speaker, Alzheimer Association of Central Ohio's Annual Fall Conference.
48. March 18, 2002. "Mild cognitive impairment: Clinical update and pathological correlates". Dean's Lecture, University of Kentucky.
49. April 5, 2002. "Venues for Alzheimer Disease Research". University of Navarre, Pamplona, Spain.
50. May 27, 2002. "Clinical update on the diagnosis and treatment of dementia". The 26th International Congress on Internal Medicine in Kyoto, Japan.
51. June 1, 2002. "Is there a preclinical stage of Alzheimer disease?" The Maurice Victor Memorial Symposium, held at Allen Memorial Medical Library, Case Western Reserve University, Cleveland, Ohio.
52. July 23, 2002. "Global measures in the early detection of dementia" in the Symposium, "Staging of Dementia: Evaluation and Treatment" at the 8th International Conference on Alzheimer Disease and Related Disorders held in Stockholm.
53. July 30, 2002. "Is Mild Cognitive Impairment Incipient Alzheimer Disease? At the National Institute of Aging's Summer Institute on Aging Research, Airlie Conference Center in Airlie, Virginia.
54. August 31, 2002. "Clinical Update on the Diagnosis and Treatment of Dementia". At the 24th National Medical Convention of the National Arab American Medical Association, held Union Station Hyatt Regency Hotel, St. Louis, Missouri.
55. Sept 13-15, 2002. "Issues in Detection and Management of Mild Cognitive Impairment". At the Master Class in Dementia, held at St John's College, Cambridge University, England.
56. November 1-2, 2002. "Mild Cognitive Impairment" and Management of Behavioral Symptoms". At the Dementia Update 2002 Symposium, held at University of Arkansas for Medical Sciences, Little Rock, Arkansas.
57. October 28, 2002. Moderator: "Ethics of Genetic Testing for Dementia Symposium" sponsored by the ADRC and the Center for the Study of Human Values at Washington University, Chase Park Plaza Hotel, St. Louis, Missouri.
58. November 26, 2002. "Clinical update on the diagnosis and treatment of Alzheimer Disease". Medical Grand Rounds at St. Luke's Hospital, St. Louis, Missouri.
59. December 3, 2002. "Identifying early signs of Alzheimer disease". A CME course: Diagnosis and Management of Alzheimer Disease: Practice Guidelines and Strategies for Early Detection, sponsored by ADRC and other organizations, held at Chase Park Plaza Hotel, St. Louis, Missouri.
60. January 17, 2003. "Dementia Update". American Academy of Neurology's Eastern Winter Conference, held in Fort Lauderdale, FL.
61. January 27, 2003. "Executive Function in Aging and Dementia - A Clinical Perspective". National Institute on Aging's conference on "Research Needs in the Evaluation of Executive Functions", held in Bethesda, MD.
62. March 7, 2003. "Treatment of Alzheimer Disease", invited speaker and panelist at the Alzheimer Disease Symposium, University of Missouri, "Life Sciences Week", sponsored by UMSTL, Molecular Biology Program and Bioinformatics Consortium, the Danforth Plant Science Center, St. Louis, Mo.

63. March 2003. 55th Annual Meeting of the American Academy of Neurology held in Honolulu, HI, I presented the following educational courses to neurologists:
 - a. March 31, "Dementia Update" in the course, 3FC.003 – "Neurology Update I".
 - b. March 31, "Clinical Characterization of MCI with Caveats", in the course 3AC.001, "Mild Cognitive Impairment: Implications for Clinicians".
 - c. April 4, "Dementia Update" in course 7FC.002 – "Neurology Update II".
 - d. April 4, "Alzheimer Disease is Under-recognized and Undertreated", in course, 7FC.007 – "Dementia Update".
 - e. April 5, Course Director for the Course 8BS.009, "Ethical Dilemmas in Dementia".
64. April 11, 2003. "Longitudinal studies and outcome of MCI", MCI Symposium held in Miami Beach, FL.
65. May 12, 2003. "Clinical update on the diagnosis and treatment of dementia". Webcast for the Alzheimer Association and the American Society of Aging.
66. May 31, 2003. "Dilemma to Diagnosis", National Capital Area Alzheimer Association George Washington University, Washington DC.
67. June 24, 2003. "Mild Cognitive Impairment", NIA's Summer Institute on Aging Research in Airlie, VA.
68. June 26, 2003. "If aging is inevitable, growing old is not!". University of Pennsylvania School of Medicine, Philadelphia, PA.
69. August 21, 2003. "Diagnosis". 11th International Congress of the International Psychogeriatrics Association, Chicago, IL.
70. August 28, 2003. 1st Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VasCog 2003) held in Goteborg, Sweden.
 - a. August 28, "Is Vascular Cognitive Impairment a relevant entity in clinical practice and research?"
 - b. August 29, "Is Alzheimer's disease a vascular disorder?"
71. September 12, 2003. "Diagnosis & Management of Early Age-Related Memory Impairment". 2nd Annual Professional Education Day. University of Arkansas Alzheimer's Disease Research Center.
72. September 13, 2003. "Scientific Breakthroughs in AD: Implications of Treating AD". Family Information Day. University of Arkansas Alzheimer's Disease Research Center.
73. September 30, 2003. "Contemporary Challenges in Alzheimer's Disease: Exploring New Treatment Approaches", AAFP Satellite Symposium, New Orleans, LA.
74. October 17, 2003. "Resolved: MCI is the earliest stage of Alzheimer's disease". Second Canadian Colloquium on Dementia, Marriott Chateau Champlain Hotel, Montreal, Quebec, Canada.
75. November 6, 2003. "The Aging Brain," Men's Health Summit, Cleveland Clinic, Cleveland, OH.
76. November 14, 2003. "Mild Cognitive Impairment and Early-Stage Alzheimer's Disease", Department of Neurology Grand Rounds at the Mayo Clinic, Rochester, MN.
77. November 15, 2003. "Update on Alzheimer Therapy-2003", Minnesota Society for Neurological Sciences, Minneapolis, MN.
78. February 13, 2004. "Dementia Update", AAN Eastern Winter Conference, Westin Hotel and Resort at Lucaya on Grand Bahamas Island.

79. February 27, 2004. "Controversies in MCI", 2nd Annual MCI Symposium, Mt. Sinai Medical Center, Miami Beach, FL.
80. March 24, 2004. "Normal aging and early diagnosis of dementia", plenary lecture, 3rd Asia-Pacific Regional Meeting of the International Working Group on Harmonization of Dementia Drug Guidelines, Bangkok, Thailand.
81. March 25, 2004. Chair, workshop entitled, "The Clinical Dementia Rating in Different Cultures", 3rd Asia-Pacific Regional Meeting of the International Working Group on Harmonization of Dementia Drug Guidelines, Bangkok, Thailand.
82. April 13, 2004. "Mild Cognitive Impairment vs. Early Stage AD", Grand Rounds, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX.
83. April 19, 2004. "Assessment of Competency in the Cognitively Impaired", two 1-hour breakout sessions, National Human Subjects Protection Conference, Chase Park Plaza Hotel, Washington University School of Medicine in collaboration with the University of Missouri – Columbia.
84. May 30, 2004. "Early-Stage Alzheimer's Disease", Korean Dementia Association, JW Marriott Hotel, Seoul, South Korea.
85. June 1, 2004. "Early Alzheimer's Disease: Diagnosis and Treatment", Yonsei University School of Medicine Neuroscience Seminar, Yonsei University, Seoul, South Korea.
86. September 9, 2004. "Aging, Mild Cognitive Impairment, and Alzheimer's Disease: Separate or Continuous Processes", First Annual Aging Forecast Conference, UCLA Center on Aging, Los Angeles, CA.
87. September 11, 2004. "Diagnosis and Treatment of Early-Stage Alzheimer's Disease", keynote speaker at the Improving Chronic Care Quality, a National Conference on Translating Geriatric Research into Practice, Sinclair School of Nursing at the University of Missouri, Columbia in Columbia, MO.

ACTIVE RESEARCH SUPPORT:

Government/Other Sponsored Research

Role: Principal Investigator; Director-Project 1; Director-Core A; Director-Core E
 Title: Healthy Aging and Senile Dementia (HASD); **P01 AG03991**
 Duration: 01/01/04 - 12/31/08
 Amount: \$---

Role: Principal Investigator; Director-Clinical Core; Co-Director-Admin. Core
 Title: Alzheimer's Disease Research Center (ADRC); **P50 AG05681**
 Duration: 5/01/01 - 4/30/05
 Amount: \$---

Role: Principal Investigator, (Supplement)
 Title: Driving and Dementia in Older Adults: Training Rural Physicians in Evidence-Based Assessment and Cessation Strategies. Collaborative project between Washington University, St. Louis University, the Alzheimer's Association and the American Medical Association is a CME Workshop for clinicians and health providers in Missouri.
 Duration: 1/1/04-4/30/04
 Amount: \$---

Role: Principal Investigator, --- Site
 Title: Alzheimer's Disease Cooperative Study- --- Committee; ---
 Duration: 7/01/01 - 6/30/06
 Amount: \$224,241

Role: Principal Investigator
 Title: Naturally Occurring Retirement Communities (NORC) ---
 Duration: 08/01/02-12/31/04
 Amount: \$---)

Role: Principal Investigator
 Title: ---
 Duration: 08/01/03 – 07/31/08
 Amount: \$---

Role: Principal Investigator
 Title: Neuropathology of Nondemented Aging, **NIA U01 AG16974**
 Duration: 7/01/01-6/30/04
 Amount: \$255,468

Role: Principal Investigator
 Title: Antecedent Biomarkers for Alzheimer's Disease (Anonymous Foundation)
 Duration: 04/01/03 to 03/31/04
 Amount: \$---

Role: Investigator
 Title: Cortical degeneration and treatment response in DAT, R01 AG60883 (---)
 Duration: 12/01/00-11/30/04
 Amount:

Role: Consultant
 Title: A Longitudinal Study of Hazardous Drivers with Dementia, RO1 AG16335-01A2 (---)
 Duration: 10/01/00 – 09/30/05
 Amount:

Industry Sponsored Research

None currently

PAST RESEARCH SUPPORT

Government/Other Sponsored Research

Role: Principal Investigator; Director-Project 1; Director-Core A; Director-Core E
 Title: Healthy Aging and Senile Dementia (HASD); ---
 Duration: 01/01/99 - 12/31/03
 Amount: \$---

Role: Principal Investigator
 Title: Cognitive Change in Cerebrovascular Disease; ---
 Duration: 1/1/96 - 12/31/00, ---
 Amount: \$---

Role: Principal Investigator
 Title: Caregiver Burden for Demented Persons in Rural Missouri, ---
 Duration: 11/1/91 - 5/31/92

Amount: \$---

Role: Principal Investigator, --- subcontract
 Title: Consortium to Establish a Registry for Alzheimer's Disease, ---
 Duration: 9/1/89 - 8/31/94
 Amount: \$---

Role: Principal Investigator
 Title: Molecular genetics of hereditary dysphasic dementia, ---
 Duration: 12/1/93 - 11/30/94
 Amount: \$---

Role: Director-Core A, Project Leader - Project 3
 Title: Healthy Aging and Senile Dementia (HASD); ---
 Duration: 01/01/89 - 12/31/94
 Amount: \$---

Role: Director-Clinical Core
 Title: ---; ---
 Duration: 5/01/90 - 4/30/95
 Amount: Clinical Core - \$---

Role: Principal Investigator
 Title: Alzheimer's Disease Coop Study Unit - A double-blind, placebo-controlled multi-center study to examine the safety and efficacy of Selegiline and a-Tocopherol in the Treatment for Alzheimer's disease; ---
 Duration: 1/25/92 to 9/1/95
 Amount: \$---

Role: Principal Investigator
 Title: Attention, Cognition, and Driving Performance in SDAT; ---
 Duration: 4/01/92 - 9/30/95
 Amount: \$---

Role: Principal Investigator
 Title: Multi-Center Study of Alzheimer's Disease (--- Site) ---
 Duration: 9/1/93 - 8/31/96
 Amount: \$---

Role: Principal Investigator, ---
 Title: Alzheimer's Disease Cooperative Study-A multi-center trial of Prednisone in Alzheimer's disease;
 Duration: 11/1/94 to 8/31/96
 Amount: \$---

Role: Clinical Task Force Leader
 Title: Consortium to Establish a Registry for Alzheimer's Disease, ---
 Duration: 9/1/94 - 8/31/97
 Amount: \$---

Role: Principal Investigator, **Washington University Site**
 Title: Alzheimer's Disease Cooperative Study -A multi-center, double-blind, placebo-controlled study of estrogen replacement therapy in patients with mild to moderate Alzheimer's disease. AG10483 NIA/NIA
 Duration: 9/1/95 - 2/1/98
 Amount: \$32,780

Industry Sponsored Research

Role: Principal Investigator
 Title: A double-blind, placebo-controlled, multicenter study of tacrine in Alzheimer's disease. ---
 Duration: 7/27/87 - 1/14/88
 Amount: \$---

Role: Principal Investigator
 Title: Protocol 310: A double-blind, placebo controlled, tolerance and safety study of HP029 in patients with Alzheimer's disease. ---
 Duration: 10/1/89 - 9/30/90
 Amount: \$---

Role: Principal Investigator
 Title: Safety and efficacy of long term use of oxiracetam in the treatment of patients with cognitive impairment associated with dementia of the Alzheimer type, ---
 Duration: 1/1/90 - 2/28/92
 Amount: \$---

Role: Principal Investigator
 Title: Oxiracetam in the treatment of patients with cognitive impairment associated with dementia of the Alzheimer's type, ---
 Duration: 4/1/90 - 12/31/1992
 Amount: \$---

Role: Principal Investigator
 Title: A double-blind, placebo-controlled, parallel-group, high dose study of tacrine in patients with Alzheimer's disease. ---
 Duration: 11/1/91 - 1/31/93
 Amount: \$---

Role: Principal Investigator
 Title: An open- label study of DuP996 30 mg TID (90 mg daily) in patients with mild to moderate dementia of the Alzheimer type, ---.
 Duration: 10/1/92- 4/29/93
 Amount: \$---

Role: Principal Investigator
 Title: Cognex Access Program, ---
 Duration: 4/1/92 - 1/31/94
 Amount: \$---

Role: Principal Investigator
 Title: Protocol ---: A double-blind, placebo-controlled, parallel group, dose-range finding study of lazabemide in patients with Alzheimer's disease,---.
 Duration: 3/1/93 - 4/1/95
 Amount: \$---

Role: Principal Investigator
 Title: A controlled study of ondansetron in the treatment of primary degenerative dementia of the Alzheimer type. ---
 Duration: 7/30/93 - 7/29/95
 Amount: \$---

Role: Principal Investigator

Title: A 12-week, double-blind, placebo-controlled, parallel-group, dose-response, multi-center study of CI-979 in patients with Alzheimer's disease; ---
 Duration: 11/1/94 to 9/1/95
 Amount: \$---

Role: Principal Investigator
 Title: 6 Month efficacy and safety study of Besipirdine Hydrochloride (HP 749) in patients with Alzheimer's disease; ---
 Duration: 4/1/94 - 12/31/95
 Amount: \$---

Role: Principal Investigator
 Title: A double-blind, placebo-controlled, trial to evaluate the safety and efficacy of metrifonate (BAY A 9826) in patients with probable Alzheimer's disease. ---
 Duration: 10/31/95 - 3/31/96
 Amount: \$---

Role: Principal Investigator
 Title: A double-blind, placebo-controlled, multicenter pilot study to evaluate the safety and tolerability of metrifonate (BAY a 9826) in patients with probable Alzheimer's disease, ---
 Duration: 5/1/95 - 11/30/96
 Amount: \$----

Role: Principal Investigator
 Title: The Cognex Neuropsychiatric Testing and Assessment of Caregiver Time. ---
 Duration: 5/30/96 - 6/30/97
 Amount: \$-----

Role: Principal Investigator
 Title: A multi-center, open-label study of the safety and tolerability of Metrifonate (BAY A 9826) in patient with probable Alzheimer's disease. The extension to protocol D95-018. ---
 Duration: 1/1/96 - 10/30/97
 Amount: \$----

Role: Principal Investigator
 Title: A multi-center, open-label study of the safety and tolerability of Metrifonate (BAY A 9826) in patients with probable Alzheimer's disease; The extension to protocol X93-029. ---
 Duration: 9/95-10/30/97
 Amount: \$---

Role: Principal Investigator
 Title: A multicenter, open-label, study of the safety and tolerability of metrifonate (BAY A 9826) in patients with probable Alzheimer's disease, ----
 Duration: 7/31/95 - 11/1/97
 Amount: \$---

Role: Principal Investigator
 Title: A 24 week, double-blind, placebo-controlled, parallel group, fixed dose study of the efficacy and tolerability of SB202026 25 ug bid. and SB202026 50 ug o.d. in patients suffering from dementia of the probable Alzheimer's type. ----
 Duration: 3/96 - 12/31/97
 Amount: \$---

Role: Principal Investigator
 Title: An open extension study of the long-term safety and efficacy of -- (25 ug bid or 50 ug bid) in patients suffering from dementia of the probable Alzheimer's type. ---

Duration: 9/96 - 2/15/98
Amount: \$---

Role: Principal Investigator
Title: A multi-center, double-blind, placebo-controlled study of Acetyl-L-Carnitine in patients with age-defined (between 45 and 65 years of age) Alzheimer's disease; ---
Duration: 9/95 to 1998
Amount: \$---

Role: Principal Investigator
Title: Long-term treatment with Metrifonate (BAY A 9826) for patients with probably Alzheimer's disease. The extension to Protocol Y93-029 and X95-018. ---
Duration: 4/7/97 - 8/30/98
Amount: \$---

Role: Principal Investigator
Title: An open label study to evaluate the safety and efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d. (12 mg/day) of ExelonTM in patients with mild to severe probable Alzheimer's disease in community setting. ---
Duration: 1/2/97 to 1999
Amount: \$---

Role: Principal Investigator
Title: A double-blind randomized, placebo-controlled, comparative study of Celecoxib (SC-58635) for the Inhibition of Progression of Alzheimer's Disease, ---
Duration: 5/27/97 to 4/26/99
Amount: \$

Role: Principal Investigator
Title: An open-label evaluation of the long term efficacy and safety of Celecoxib (SC-58635) in Alzheimer's disease, ---
Duration: 8/25/98 to 4/26/01
Amount: \$

Role: Principal Investigator
Title: Placebo controlled evaluation of galantamine in the treatment of Alzheimer's disease: Safety and efficacy under a slow-titration regimen, ---
Duration: 11/10/98 to 12/31/99
Amount: \$

Role: Principal Investigator
Title: Neuropathological Correlates of Nondemented Aging - This is a collaborative project between --- to determine what neuropathology characterizes healthy aging.
Duration: 07/01/01-06/30/02

CLINICAL RESPONSIBILITIES

Departmental:

Section Head, Dementia and Aging, Department of Neurology,
Neurology Outpatient Committee

Medical School:

Specialty Capitation Design Team
Research Support Services Assessment Project Steering Committee
Chair, Faculty Retreat Steering Committee on Patient-Oriented Research

ACTIVE TEACHING RESPONSIBILITIES

Attending
 WUMS II - "Disease of the Nervous System"
 M35-851 (Coursemaster) - Fourth Year Elective "Clinical Aspects of Aging and Dementia"
 M04-582 (Coursemaster) - First Year Elective "Alzheimer's Disease"
 Preceptor -
 First year students, Clinical Neurology
 Faculty-student advisor
 Summer students
 Clinical Neuroscience Lecture (Neurology Residents)
 Small group faculty leader – 1st year medical students course on Health Promotion and Disease Prevention

PEER-REVIEWED PUBLICATIONS:

1. **Morris JC**, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia and the Pick-Alzheimer spectrum. *Annals of Neurology* 1984;16:455-466.
2. Knesevich JW, Toro FR, **Morris JC**, LaBarge E. Aphasia, family history, and the longitudinal course of senile dementia of the Alzheimer type. *Psychiatry Research* 1985;14:255-263.
3. Torack RM, **Morris JC**. Mesolimbocortical dementia. *Archives of Neurology* 1986;43:1074-1078.
4. **Morris JC**, Dodson WE, Hatlelid JM, Ferrendelli JA. Phenytoin and carbamazepine, alone and in combination: Anticonvulsant and neurotoxic effects. *Neurology* 1987;37:1111-1118.
5. Rubin EH, **Morris JC**, Storandt M, Berg L. Behavioral changes in patients with mild senile dementia of the Alzheimer type. *Psychiatry Research* 1987;21:55-62.
6. Rezek DL, **Morris JC**, Fulling KH, Gado MH. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. *Neurology* 1987;37:1365-1368.
7. Rubin EH, **Morris JC**, Berg L. The progression of personality changes in dementia. *Journal of the American Geriatrics Society* 1987;35:721-725.
8. **Morris JC**, Rubin EH, Morris EJ, Mandel S. Senile dementia of the Alzheimer type. An important risk factor for serious falls. *Journal of Gerontology* 1987;42:412-417.
9. Burke WJ, Miller JP, Rubin EH, **Morris JC**, Coben LA, Duchek J, Wittels IG, Berg L. Reliability of the Washington University Clinical Dementia Rating. *Archives of Neurology* 1988;45:31-32.
10. **Morris JC**, Fulling K. Early Alzheimer's disease: Diagnostic considerations. *Archives of Neurology* 1988;45:345-349.
11. Faber-Langendoen K, **Morris JC**, Knesevich JW, LaBarge E, Berg L. Aphasia in senile dementia of the Alzheimer type. *Annals of Neurology* 1988;23:365-370.
12. Berg L, Miller JP, Storandt M, Duchek J, **Morris JC**, Rubin EH, Burke WJ, Coben LA. Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. *Annals of Neurology* 1988;23:477-484.
13. **Morris JC**, McKeel DW Jr, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. *Annals of Neurology* 1988;24:17-22.

14. Torack RM, **Morris JC**. The association of ventral tegmental area histopathology with adult dementia. *Archives of Neurology* 1988;45:497-501.
15. Burke WJ, Rubin EH, **Morris JC**, Berg L. Symptoms of "depression" in senile dementia of the Alzheimer type. *Alzheimer's Disease and Associated Disorders* 1988;2:356-362.
16. **Morris, JC**, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Clinical and Neuropsychological Assessment of Alzheimer's Disease. *Psychopharmacology Bulletin* 1988;24:641-652.
17. Rubin EH, **Morris JC**, Grant EA, Vendegna T. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. *Archives of Neurology* 1989;46:379-382.
18. **Morris JC**, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease - a role for extranigral factors? *Archives of Neurology* 1989;46:651-657.
19. Torack RM, **Morris JC**. Vascular glycosaminoglycans in periventricular leukoencephalopathy. *Acta Neuropathologica* 1989;78:492-496.
20. **Morris JC**, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology* 1989;39:1159-1165.
21. McCulla MM, Coats M, Van Fleet N, Duchek J, Grant EA, **Morris JC**. Reliability of nurse specialists in the staging of dementia. *Archives of Neurology* 1989;46:1210-1211.
22. Rubin EH, Kinscherf DA, **Morris JC**. Personality and dementia. *Bulletin of Clinical Neurosciences* 1989;54:88-94.
23. **Morris JC**, Gado M, Torack RM, McKeel DW Jr: Binswanger's disease or artifact: A clinical, neuro-imaging, and pathological study of periventricular white matter changes in Alzheimer's disease. Advances in Neurology, Vol. 51: Alzheimer's Disease, edited by Wurtman RJ, Corkin SH, Growdon JH. New York: Raven Press, 1990, pp. 47-52.
24. Davis PB, **Morris JC**, Grant E. Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. *Journal of American Geriatrics Society* 1990;38:129-135.
25. Green J, **Morris JC**, Sandson J, McKeel DW, Miller JW. Progressive aphasia: A precursor for global dementia? *Neurology* 1990;40:423-429.
26. **Morris JC**. Establishing diagnostic criteria for a registry for dementing diseases. *Aging: Clinical and Experimental Research* 1990;2:207-215.
27. Romanelli MF, **Morris JC**, Ashkin K, Coben LA. Advanced Alzheimer's disease: a risk factor for late-onset seizures. *Arch Neurol* 1990;47:847-850.
28. Torack RM, **Morris JC**. Tyrosine hydroxylase-like immunoreactivity in human mesolimbic system. *Neurosci Lett* 1990;116:75-80.
29. Berg L, Smith DS, **Morris JC**, Miller JP, Rubin EH, Storandt M, Coben LA. Mild senile dementia of the Alzheimer type: 3. Longitudinal and cross-sectional assessment. *Ann Neurol* 1990;28:648-652.
30. **Morris JC**, McKeel DW, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L. Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathological distinction from normal aging. *Neurology* 1991;41:469-478.

31. Wipplod FJ, Gado M, **Morris JC**, Duchek J, Grant EA. Senile dementia and healthy aging: A longitudinal CT study. *Radiology* 1991;179:215-219.
32. Price JL, Davis PB, **Morris JC**, White DL. The distribution of tangles, plaques, and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiology of Aging* 1991;12:295-312.
33. **Morris JC**, McManus DQ. The neurology of aging: Normal versus pathological change. *Geriatrics* 1991;46:47-54.
34. Edwards DF, Deuel RK, Baum CM, **Morris JC**. A quantitative analysis of apraxia in senile dementia of the Alzheimer type: Stage-related differences in prevalence and type. *Dementia* 1991;2:142-149.
35. Berg L, Miller JP, Baty J, Rubin EH, **Morris JC**, Figiel G. Mild senile dementia of the Alzheimer type: 4. Evaluation of intervention. *Annals of Neurology* 1992;31:242-249.
36. Powers WJ, Perlmuter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, Siegel BA, **Morris JC**, Berg L. Blinded clinical evaluation of positron emission tomography for diagnosis of Alzheimer's disease. *Neurology* 1992;42:765-770.
37. Torack RM, **Morris JC**. Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. *J Neurol Transmission* 1992;4:165-171.
38. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, **Morris JC**, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS and the Tacrine Collaborative Study Group. A double-blind, placebo-controlled multicenter study of Tacrine for Alzheimer's disease. *NEJM* 1992;327:1253-1259.
39. Cole M, Winkelman MD, **Morris JC**, Simon JE, Boyd TA. Thalamic amnesia: Korsakoff syndrome due to left thalamic infarction. *J Neurol Sci* 1992;110:62-67.
40. Berg L, McKeel DW, Miller JP, Baty J, **Morris JC**. Neuropathologic indices of Alzheimer's disease in demented and nondemented people aged eighty and over. *Arch Neurol* 1993;50:349-358.
41. Rubin EH, Storandt M, Miller JP, Grant EA, Kinscherf DA, **Morris JC**, Berg L. Influence of age on clinical and psychometric assessment of subjects with very mild or mild dementia of the Alzheimer type. *Arch Neurol* 1993;50:380-383.
42. Rubin EH, Kinscherf DA, **Morris JC**. Psychopathology in younger versus older persons with very mild and mild dementia of the Alzheimer type. *Am J Psychiatry* 1993;150:639-642.
43. Hunt L, **Morris JC**, Edwards D, Wilson BS. Driving performance in persons with mild senile dementia of the Alzheimer type. *Journal of the American Geriatrics Society* 1993;41:747-753.
44. McKeel DW, Ball MJ, Price JL, Smith DS, Miller JP, Berg L, **Morris JC**. Interlaboratory histopathologic assessment of Alzheimer neuropathology: Different methodologies yield- comparable diagnostic results. *Alzheimer Disease and Associated Disorders* 1993;7:136-151.
45. Kaniecki R, **Morris JC**. Reversible paraneoplastic limbic encephalitis. *Neurology* 1993; 43:2418-2419.
46. **Morris JC**. The Clinical dementia rating (CDR): Current version and scoring rules. *Neurology* 1993;43:2412-2414.

47. **Morris JC**, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive changes in the longitudinal assessment of Alzheimer's disease. *Neurology* 1993;43:2457-2465.
48. Schellenberg GD, Payami H, Wijsman EM, Orr HT, Goddard KAB, Anderson L, Nomens E, White JA, Alonso E, Ball MJ, Kaye J, **Morris JC**, Chui H, Sadovnick AD, Heston LL, Martin GM, Bird TD. Chromosome 14 and late-onset familial Alzheimer's disease. *Am J Hum Genetics* 1993;53:619-628.
49. Drachman DA, Swearer JM, for the Collaborative Study Group. Driving and Alzheimer's disease: The risk of crashes. *Neurology* 1993;43:2448-2456.
50. Goddard K, Nemens E, White J, Alonso E, Taylor T, Ball M, Kaye J, **Morris JC**, Chui H, Sadovnick A, Martin G, Larson E, Heston L, Bird T, Schellenberg G. The Apolipoprotein E/CII gene cluster and late-onset Alzheimer disease. *Am J Hum Genetics* 1994;54:631-642.
51. Silverman J, Raiford K, Edland S, Fillenbaum G, **Morris JC**, Clark C, et al. CERAD Part VI. family history assessment: a multi-center study of relatives of AD probands and non-demented spouse controls. *Neurology* 1994;44:1253-1259.
52. **Morris, JC**. Conflicts of interest: Research and clinical care. *Alzheimer's Disease and Associated Disorders* 1994;8:S4:49-57.
53. Talbot C, Lendon C, Craddock N, Shears S, **Morris JC**, Goate A. Protection against Alzheimer's disease with apoE ϵ 2. *Lancet* 1994;343:1432-1433.
54. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, the Tacrine Study Group, **Morris JC**, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. *JAMA* 1994;271:985-991.
55. Gates GA, Karzon RK, Garcia P, Peterein J, Storandt M, **Morris JC**, Miller JP. Auditory dysfunction in aging and senile dementia of the Alzheimer's type. *Arch Neurol* 1995;52:626-634.
56. Davis PC, Gearing M, Gray L, Mirra SS, **Morris JC**, Edland SD, Lin T, Heyman A. The CERAD Experience, Part VIII. Neuroimaging-neuropathology correlates of temporal lobe changes in Alzheimer's disease. *Neurology* 1995;45:178-179.
57. Galasko D, Edland MS, **Morris JC**, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over three years. *Neurology* 1995;45:1451-1455.
58. Clark RF, Hutton M, Fuldner R, Froehlich S, Karran E, Talbot C, Crook R, Lendon C, Prihar G, He C, Korenblat K, Martinez A, Wragg M, Busfield F, Behrens MI, Myers A, Norton J, **Morris JC**, Nehta N, Pearson C, Lincoln S, Baker M, Duff K, Zehr C, Houlden H, Ruiz A, Ossa J, Lopera F, Arcos M, Madrigal L, Colinge J, Humphreys C, Asworth T, Sarnier S, Cline R, Philips C, Venter C, Forsell L, Axelman K, Lilius L, Johnston J, Cowburn R, Viitanen M, Winblad B, Kosik K, Haltia M, Poyhonen M, Dickson D, Mann D, Neary D, Snowden J, Lannfelt L, Rossor M, Roberts GW, Adams M, Hardy J and Goate A. The structure of Presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. *Nature Genetics* 1995;11:219-222.
59. Wragg MA, Talbot CJ, **Morris JC**, Lendon CL, and Goate AM. No association found between Alzheimer's disease and mitochondrial tRNA glutamine gene variant. *Neuroscience Letters* 1995;201:107-110.

60. Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, **Morris JC**. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease. A CERAD analysis, Part XII. *Neurology* 1996;46:136-141.
61. Fillenbaum GG, Huber MS, Beekly D, Henderson VW, Mortimer J, **Morris JC**, Harrell LE. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIII. Obtaining autopsy in Alzheimer's disease. *Neurology* 1996;46:142-145.
62. **Morris JC**, Storandt M, McKeel DW, Rubin E, Price JL, Grant EA, Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. *Neurology* 1996;46:707-719.
63. Talbot C, Houlden H, Craddock N, Crook R, Hutton M, Lendon C, Prihar G, **Morris JC**, Hardy J and Goate A. Polymorphism in AACT gene lowers age of onset of Alzheimer's disease. *Neuroreport* 1996;7:534-536.
64. Wragg M, Hutton M, Talbot C, Busfield F, Han SW, Lendon C, Clark RF, **Morris JC**, Edwards D, Pfeiffer E, Crook R, Prihar G, Phillips H, Baker M, Rossor M, Houlden H, Karran E, Roberts G, Craddock N, Hardy, J. Genetic association between an intronic polymorphism in presenilin 1 gene and late onset Alzheimer's disease. *Lancet* 1996;347:509-512.
65. Gomez-Isla T, Price JL, McKeel DW, **Morris JC**, Growdon JH, and Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *J Neurosci* 1996;16:4491-4500.
66. Csernansky JG, Bardgett ME, Sheline YI, **Morris JC**, Olney JW. CSF excitatory amino acids and severity of illness in Alzheimer's disease. *Neurology* 1996;46:1715-1720.
67. Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, **Morris JC**. Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance. *Neurology* 1996;47:254-256.
68. Norton JB, **Morris JC**. Obtaining consent for autopsy in dementia research: The Memory and Aging Project experience. *Am J of Alzheimer's Care and Related Disorders and Research* 1996;11:2-6.
69. Ellis RJ, Olichney JM, Thal L, Mirra SS, **Morris JC**, Beekly D, Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD Experience, Part XV. *Neurology* 1996;46:1592-1596.
70. O'Connor DW, Blessed G, Cooper B, Jonker C, **Morris JC**, Presnell IB, Ames D, Kay DWK, Bickel H, Schaefele M, Wind A, Coats M., and Berg L. Cross-national interrater reliability of dementia diagnosis and factors associated with disagreement. *Neurology* 1996; 47:1194-1199.
71. Porter FL, Malhotra KM, Wolf CM, Smith MC, Miller JP, and **Morris JC**. Dementia and response to pain in the elderly. *Pain* 1996; 68:413-421.
72. Eastwood MR, Amaducci L, Brayne C, Broe T, Burns A, Copeland J, Dickens B, Goate A, Hachinski V, Henderson S, Jolles J, **Morris JC**, Ritchie K, Roses A, Rossor M, Schellenberg G, Skoog I, Storandt M, Tallis R, Whitehouse P, Clark S, Evans I, Horton R, and Sharp D. The challenge of the dementias. *Lancet* 1996;347:1303-1307.
73. Olin JT, Schneider LS, Doody RS, Clark CM, Ferris S, **Morris JC**, Reisberg B, Schmitt F. Evaluating global change in Alzheimer's disease: Identifying consensus. *J Geriatr Psychiatry Neurol* 1996;9:176-180.
74. Fillenbaum GG, Peterson B, **Morris JC**. Estimating the validity of the clinical dementia rating scale: The CERAD experience. *Aging Clin Exp Res* 1996;8:379-386.

75. Schafer K, Thomas R, Galasko D, Morris JC, Whitehouse P, Bochenek J, Thal L. Informed consent issues when including genetic testing in clinical trials. *Control Clin Trials* 1996 17:S130-S131.
76. Hulette C, Nochlin D, McKeel D, **Morris JC**, Mirra SS, Sumi SM, and Heyman A. Clinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases. *Neurology* 1997;48:668-672.
77. Lendon CL, Talbot CJ, Craddock NJ, Wragg M, Han SW, **Morris JC**, Goate A. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. *Neuroscience Letters* 1997;222:187-190.
78. **Morris JC**, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P. Clinical dementia rating training and reliability in multicenter studies: The Alzheimer's Disease Cooperative Study experience. *Neurology* 1997;48:1508-1510.
79. Hunt LA, Carr D, Ducheck JM, Grant EA, Buckles V, Murphy CF, **Morris JC**. Reliability and validity of the Washington University road test: A performance-based assessment for drivers with dementia of the Alzheimer type. *Arch Neurol* 1997;54:707-712.
80. Clark CM, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, **Morris JC**, Fillenbaum GG, Heyman A, and the CERAD collaborators. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD study. *Neurology* 1997;49:70-75.
81. Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, **Morris JC**, Rogers S, Sawada T. International working group on harmonization of dementia drug guidelines: Consensus statement on clinical global measures. *Alzheimer Dis Assoc Dis* 1997;11:Suppl. 3:8-18.
82. Reed LA, Grabowski TJ, Schmidt ML, **Morris JC**, Solodkin A, Van Hoesen GW, Schelper RL, Trojanowski JQ. Autosomal dominant dementia with widespread neurofibrillary tangles. *Ann Neurol* 1997;42:564-572.
83. Knopman DS, and **Morris JC**. An update on primary drug therapies for Alzheimer's disease. *Arch Neurol* 1997;54:1406-1409.
84. Small GW, Rabins PV, Barry P, Buckholtz N, DeKosky S, Ferris S, Finkel SI, Gwyther L, Khachaturian ZS, Lebowitz B, McRae T, **Morris JC**, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri L, Tune L. Diagnosis and treatment of Alzheimer's disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. *JAMA* 1997;278:1363-1371.
85. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux RH, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. The APOE and Alzheimer Disease Meta Analysis Consortium, **Morris JC**. Effects of age, gender and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. *JAMA* 1997;278:1349-1356.
86. Schafer K, Ernesto C, Sano M, Mackell J, Thomas R, **Morris JC**. Clinical monitoring of rating scales in multicenter clinical trials. *Control Clin Trials* 1997;18:S57.
87. Rubin EH, Storandt M, Kinscherf DA, Grant EA, **Morris JC**, Berg L. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. *Arch Neurol* 1998;55:395-401.

88. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, **Morris JC**, Frank A, Vazquez J, Goate A. and Valdivieso F. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. *Nature Genetics* 1998;18:69-71.
89. Mayeux RH, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M-X, Phelps CS, Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease, **Morris JC** et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. *N Engl J Med* 1998;338:506-516.
90. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, **Morris JC**, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and ApoE genotype. *Arch Neurol* 1998;55:326-335.
91. Kanne SM, Balota DA, Storandt M, McKeel Jr. DW, **Morris JC**. Relating anatomy to function in Alzheimer's disease: Neuropsychological profiles predict regional neuropathology five years later. *Neurology* 1998;50:979-985.
92. Goldman WP, Baty JD, Buckles VD, Sahrman S, **Morris JC**. Cognitive and motor functioning in Parkinson's disease with and without questionable dementia. *Arch Neurol*. 1998;55:674-680.
93. Duchek JM, Hunt L, Ball K, Buckles V, and **Morris JC**. Attention and driving performance in Alzheimer's disease. *J Gerontology: Psychological Sciences* 1998;53B:2:130-141.
94. **Morris JC**, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka B, Gulanski B. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease. *Neurology* 1998; 50:1222-1230.
95. Lendon CL, Lynch T, Norton J, Busfield F, Craddock N, Chakraverty S, Gopalakrishnan G, Shears SD, Grimmett W, Wilhelmsen KC, Hansen L, McKeel DW, **Morris JC**, Goate A. Hereditary dysphasic disinhibition dementia: A frontal lobe dementia linked to 17q21-22. *Neurology* 1998;50:1546-1555.
96. Hutton M, Lendon CL, Rizzu P, Baker M, Freilich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, **Morris JC**, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Nayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, and Heutink P. Association of missense and 5'-splice-site mutations in *tau* with the inherited dementia FTDP-17. *Nature* 1998;393:702-706.
97. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Geschwind DH, Bird TD, McKeel D, **Morris JC**, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee V M-Y. Mutation-specific functional impairments in distinct tau isoforms of hereditary frontotemporal dementia and parkinsonism linked to chromosome17: Genotype predicts phenotype. *Science* 1998;282:1914-1917.
98. Smith MC, Goldman WP, Janer KW, Baty JD, and **Morris JC**. Cognitive speed in nondemented Parkinson's disease. *J Int Neuropsychol Soc* 1998;4:584-592.
99. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, García MA, Lendon CL, Han SW, **Morris JC**, Vázquez J, Goate A, Valdivieso F. Risk for Alzheimer's disease correlates with the transcriptional activity of the APOE gene. *Human Molecular Genetics* 1998;7:1887-1892.
100. Tractenberg RE, Schafer K, Thomas RG, Petersen R, **Morris JC**. Agreement on CDR ratings by committee. *Control Clin Trials* 1998;19:S89.

101. Goldman WP, Baty JD, Buckles VD, Sahrmann S, **Morris JC**. Motor dysfunction in mildly demented Alzheimer's disease subjects without extrapyramidal signs. *Neurology* 1999; 53:956-962.
102. Price JL, **Morris JC**. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann Neurol* 1999; 45:358-368.
103. Wavrant-DeVrière F, Rudrasinham V, Lambert J-C, Chakraverty S, Kehoe P, Crook R, Amouyel P, Wu W, Holmans P, Rice F, Perez-Tur J, Frigard B, **Morris JC**, Carty S, Cattel D, Tunstall N, Lovestone S, Peterson RC, Chartier-Harlin M-C, Goate A, Owen MJ, Williams J, Hardy J. No association between the alpha-2 macroglobulin 11000V polymorphism and Alzheimer's disease. *Neuroscience Letters* 1999;262:137-139.
104. Houlden H, Rizzu R, Stevens M, de Knijff P, van Duijn CM, van Swieten JC, Heutink P, Perez-Tur J, Thomas V, Baker M, Morris H, Rossor M, Janssen JC, Petersen RC, Dodd P, Dark F, Boeve B, Dickson D, Davies P, Pickering-Brown S, Mann D, Adamson J, Lynch T, Payami H, Poorkaj P, Bird T, Schellenberg GD, Chakraverty S, Norton J, **Morris JC**, Goate A, Hutton M, and Hardy J. Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. *Neuroscience Letters* 1999;260:193-195.
105. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, **Morris JC**, Koss E, Mohs R, Heyman A, and the CERAD investigators. Variability in annual Mini-mental State examination score in patients with probable Alzheimer's disease: A clinical perspective of data from CERAD (Consortium to Establish a Registry for Alzheimer's Disease). *Arch Neurol* 1999;56:857-862.
106. Kawas CH, Clark CM, Farlow MR, Knopman DS, Marson D, **Morris JC**, Thal LJ, Whitehouse PJ. Clinical trials in Alzheimer's disease: The debate on the use of placebo controls. *Alzheimer Dis Assoc Dis* 1999;13:124-129.
107. Edwards DF, Morrow-Howell N, Baum CM, Meisel M, Depke M, Williams J, Braford T, **Morris JC**. Home-based multidisciplinary diagnosis and treatment of inner city elderly with dementia. *Gerontologist* 1999;39:483-488.
108. Rudrasingham V, Wavrant-DeVrieze F, Lamert J-C, Chakraverty S, Kehoe P, Crook R, Amouyel P, WU W, Rice F, Perez-Tur J, Frigard B, **Morris JC**, Carty S, Petersen R, Cattel D, Tunstall N, Holmans P, Lovestone S, Chartier-Harlin MC, Goate A, Hardy J, Owen MJ, Williams J. α -2 macroglobulin gene and Alzheimer disease. *Nature Genetics* 1999;22:17-19.
109. **Morris JC**. Is Alzheimer's disease inevitable with age? *J Clin Invest* 1999;104:1171-1173.
110. Wavrant-DeVrieze F, Crook R, Holmans P, Kehoe P., Owen MJ, Williams J, Roehl K, Laliiri D, Shears S, Booth J, Wu W, Goate A, Chartier-Harlin M-C, Hardy J, Perez-Tur J. Genetic variability at the amyloid- β precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. *Neuroscience Letters* 1999;269:67-70.
111. Schafer K, Thomas R, **Morris JC**, Mohs RC, Tractenberg R, Ryan-Jones R, Croot K, Coats M, Grundman M, Petersen R, Thal LJ. Standardizing the administration of complex assessment measures in multicenter clinical trials. *Control Clin Trials* 1999;20:S61.
112. Thal P, Whitehouse J. Clinical trials in Alzheimer disease: debate on the use of placebo controls. *Alzheimer Dis Assoc Disord* 1999;13:124-129.
113. Carr DB, Duchek J, **Morris JC**. Characteristics of motor vehicle crashes of drivers with dementia of the Alzheimer type. *J Am Geriatr Soc* 2000;48:18-22.

114. Rockwood K, Strang D, MacKnight C, Downer R, **Morris JC**. Interrater reliability of the Clinical Dementia Rating in a multicenter trial. *JAGS* 2000; 48:558-559.
115. Cronin-Stubbs D, DeKosky ST, **Morris JC**, Evans DA. Promoting interactions with basic scientist and clinicians: The NIA Alzheimer's Disease Data Coordinating Center. *Statist. in Med.* 2000;19:1453-1461.
116. Tariot PN, Solomon P, **Morris JC**, Kershaw P, Lilienfeld S, Parys W, Ding C, Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. *Neurology* 2000;54:2269-2276.
117. Fagan AM, Younkin LH, **Morris JC**, Fryer JD, Cole TG, Younkin SG, Holtzman DM. Differences in A β 40/A β 42 associated with CSF lipoproteins as a function of apolipoprotein E genotype. *Ann Neurol* 2000;48:201-210.
118. Chapman T, McKeel DW, **Morris JC**. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. *Neurology* 2000;55:1396-1397.
119. Carr DB, Gray SH, Baty J, **Morris JC**. The value of informant vs. individual's complaints of memory impairment in early dementia. *Neurology* 2000;55:1724-1726.
120. Wang JC, Kwon J, Shah P, **Morris JC**, Goate A. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. *Neurology* 2000;55:1644-1649.
121. Csernansky JG, Wang L, Joshi S, Miller JP, Gado M, Kido D, McKeel D, **Morris JC**, Miller MI. Early DAT is distinguished from aging by high dimensional mapping of the hippocampus. *Neurology* 2000;55:1636-1643.
122. Kwon JM, Nowotny P, Shah PK, Chakraverty S, Norton J, **Morris JC**, Goate AM. Tau polymorphisms are not associated with Alzheimer's disease. *Neuroscience Letters* 2000;284:77-80.
123. Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, **Morris JC**, Olney JW, McKeel DW, Jr. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. *Arch Gen Psychiatry* 2000;57:1165-1173.
124. **Morris JC**, Hurst E, McKeel DW, Price JL, Rubin E, Grant EA, Berg L. Healthy brain aging in nonagenarians and centenarians. *Neurobiol Aging* 2000;21(1S):S280-S281.
125. Buckner RL, Snyder AZ, Sanders AL, Raichle ME, **Morris JC**. Functional brain imaging of nondemented and demented older adults. *J Cog Neuroscience* 2000; 12:(supplement 2), 24-34.
126. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, **Morris JC**. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. *Neurology* 2001;56:127-129.
127. Grutzendler J, **Morris JC**. Cholinesterase inhibitors for Alzheimer's disease. *Drugs* 2001;61 (1):41-52.
128. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW Jr, Rubin EH, **Morris JC**. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. *Neurology* 2001;56:361-367.
129. **Morris JC**, Storandt M, Miller JP, McKeel DW Jr, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer's disease. *Arch Neurol* 2001;58:397-405.
130. Goldman WP, **Morris JC**. Evidence that age-associated memory impairment is not a normal variant of aging. *Alzheimer Disease and Associated Disorders* 2001;15:72-79.

131. Price JL, McKeel DW Jr, **Morris JC**. Synaptic loss and pathological change in older adults—aging versus disease? *Neurobiol Aging* 2001; 22:351-352.
132. Rubin EH, Veiel LL, Kinscherf DA, **Morris JC**, Storandt M. Clinically significant depressive symptoms and very mild to mild dementia of the Alzheimer type. *Int J Geriatr Psychiatry* 2001;16:694-701.
133. Josephson SA, Schmidt RE, Millsap P, McManus DQ, **Morris JC**. Autosomal dominant Kufs' disease: A cause of early-onset dementia. *J Neurol Sci* 2001; 188: 51-60.
134. Mohs RC, Doody RS, **Morris JC**, Leni JR, Rogers SL, Perdomo CA, Pratt RD, for the "312" Study Group. A 1-year, placebo-controlled preservation of functional survival study of donepezil in AD patients. *Neurology* 2001;57:481-488.
135. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, **Morris JC**. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. *Arch Neurol* 2001; 58:1395-1402.
136. **Morris JC**, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. *J Mol Neurosci*. 2001; 17:2:101-118.
137. Kovach MJ Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, Shanks CA, Gregg G, Al-Lozi MT, Miller T, Rakowicz W, Lopate G, Florence J, Glosser G, Simmons Z, **Morris J**, Whyte MP, Pestronk A, Kimonis VE. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: Hereditary inclusion body myopathy, Paget disease of bone and frontotemporal dementia. *Mol Gen Metab* 2001; 74:458-475.
138. Tractenberg RE, Schafer K, **Morris JC**. Inter-observer disagreement on Clinical Dementia Rating (CDR) assessments and implications for training. *ADAD* 2001; 15:3:155-161.
139. Petersen RC, Doody R, Kurz A, Mohs RC, **Morris JC**, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. *Arch Neurol* 2001; 58:1985-1992.
140. Nowotny P, Kwon JM, Chakraverty S, Nowotny V, **Morris JC**, Goate AM. Association studies using novel polymorphisms in BACE1 and BACE2. *Neuroreport*. 2001; 12:1799-1802.
141. Winbald B, Brodaty H, Gauthier S, **Morris JC**, Orgogozo J-M, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? *Int J. Geriatr Psychiatry* 2001; 16:653-666.
142. Myers A, De-Vrieze FW, Holmans P, Hamshere M, Crook R, Compton D, Marshall H, Meyer D, Shears S, Booth J, Ramic D, Knowles H, **Morris JC**, Williams N, Norton N, Abraham R, Kehoe P, Williams H, Rudrasingham V, Rice F, Giles P, Tunstall, N, Jones L, Lovestone S, Williams J, Owen MJ, Hardy J, and Goate A. Full genome screen for Alzheimer disease: Stage II analysis. *American Journal of Medical Genetics* 2002; 114:235-244.
143. Logan JM, Sanders AL, Snyder AZ, **Morris JC**, Buckner RL. Under-recruitment and non-selective recruitment: Dissociable neural mechanisms associated with cognitive decline in older adults. *Neuron* 2002; 33:827-840.
144. Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, Harris JM, Artiga MJ, Hernandez D, Kwon JM, Frigard B, Petersen RC, Cumming AM, Pasquier F, Sastre I, Tienari PJ, Frank A, Sulkava R, **Morris JC**, St. Clair D, Mann DM, Wavrant-DeVrière F, Ezquerra-Trabalon M, Amouyel P, Hardy J, Haltia M, Valdivieso F, Goate AM, Pérez-Tur J, Lendon CL, and Chartier-Harlin MC. Contribution of *APOE* promoter polymorphisms to Alzheimer's disease risk. *Neurology* 2002; 59:59-66.

145. Han X, Holtzman DM, McKeel DW Jr, Kelley J, **Morris JC**. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. *J. Neurochem* 2002; 82:809-818.
146. Csernansky JG, Miller JP, McKeel D, **Morris JC**. Relationships among CSF biomarkers in dementia of the Alzheimer type. *Alzheimer's Disease Associate Disorders* 2002; 16:3:144-149.
147. Powlishta KK, Von Dras DD, Stanford A, Carr DB, Tsering C, Miller JP, **Morris JC**. The clock drawing test as a screen for very mild dementia: A comparison of six scoring methods. *Neurology* 2002; 59:898-903.
148. Storandt M, Grant EA, Miller PJ, **Morris JC**. Rates of progression in mild cognitive impairment and early Alzheimer disease. *Neurology* 2002; 59:1034-1041.
149. Galvin JE, Lee SL, Perry A, Havlioglu N, McKeel DW, and **Morris JC**. Familial dementia with Lewy bodies: Clinicopathological analysis of two kindreds. *Neurology* 2002; 59:1079-1082.
150. Karlawish JHT, Knopman D, Clark CM, **Morris JC**, Marson D, Whitehouse PJ, Kawas CH. Informed consent for Alzheimer's Disease clinical trials: A survey of clinical investigators. *IRB: Ethics & Human Research* 2002; 24:5:1-5.
151. Cacchione PZ, Powlishta KK, Grant EA, Buckles VD, **Morris JC**. Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. *JAGS* 2003; 51:819-823.
152. Xiong C, Miller JP, **Morris JC**. Testing correlation of cognitive decline at stages of dementia. *Journal of Alzheimer Disease* 2003; 5:409-418.
153. Han X, Fagan AM, Cheng H, **Morris JC**, Xiong C, Holtzman DM. CSF sulfatide is decreased in individuals with incipient dementia. *Annals of Neurology* 2003; 54:115-119.
154. Villareal DT, Grant E, Miller JP, Storandt M, **Morris JC**. Clinical outcomes of *possible* versus *probable* Alzheimer's Disease. *Neurology* 2003; 61:661-667.
155. Grundman M, Capparelli E, Kim HT, **Morris JC**, Farlow M, Heidebrink J, Hake A, Rubin EH, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ, and the Alzheimer's Disease Cooperative Study. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neurotrofin™) in mild Alzheimer's disease patients. *Life Sciences* 2003; 73:539-553.
156. **Morris JC**. Update on approved drugs for the symptomatic treatment of Alzheimer Disease. *The Neurologist* 9(5):223-224, 2003.
157. Duchek JM, Carr DB, Hunt L, Roe CM, Xiong C, Shah K, **Morris JC**. Longitudinal driving performance in early stage dementia of the Alzheimer type. *Journal of the American Geriatrics Society* 51:1342-1347, October 2003.
158. Lee BCP, Mintun M, Buckner RL, **Morris JC**. Imaging of Alzheimer's Disease. *Journal of Neuroimaging* 2003; 13(3):199-214.
159. Miller MI, Hosakere M, Barker AR, Priebe CE, Lee N, Ratnanather JT, Wang L, Gado M, **Morris JC**, Csernansky JG. Labelled cortical distance maps in the cingulate quantify cortical changes distinguishing dementia of the Alzheimer type and healthy aging. *PNAS* 2003;100(25):15172-15177.
160. Wang L, Swank JS, Glick IE, Gado MH, Miller MI, **Morris JC**, Csernansky JG. Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. *NeuroImage* 2003; Oct,20(2):667-82.

161. **Morris JC.** Dementia update 2003. *Alzheimer Disease & Associated Disorders* 2003;17(4):245-258.
162. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, **Morris JC**, McKeel DW, Farlow M, Weitlaug SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VY, Trojanowski JQ. CSF tau and β -amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? *Arch Neurology* 2003;60:1696-1702.
163. Buckles VD, Powlishta KK, Palmer JL, Coats M, Hosto T, Buckley, **Morris JC.** Understanding of informed consent by demented individuals. *Neurology* 2003;61:1662-1666..
164. Lustig C, Snyder AZ, Bhakta M, O'Brian K, McAvoy M, Raichle ME, **Morris JC**, Buckner RL. Functional deactivations: Change with age and dementia of the Alzheimer type. *PNAS* November 2003;100(24):14504-14509.
165. Wilkins CH, **Morris JC.** Understanding mild cognitive impairment;An overview of diagnosis and management. *Women's Health* 2003; 3(6)309-316.
166. Reines SA, Block GA, **Morris JC**, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC, on behalf of the Roxecoxib Protocol 091 study group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. *Neurology* 2004; 62:66-71.
167. Head D, Buckner RL, Shimony JS, Gorton LE, Akbudak E, Conturo TE, McAvoy M, **Morris JC**, Snyder AZ. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type. *Cerebral Cortex* 2004;14:410-423.
168. Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RSR, Busa E, **Morris JC**, Dale AM, Fischl B. Thinning of the cerebral cortex in aging. *Cerebral Cortex* 2004; 14:721-730.
169. Meuser TM, Boise L, **Morris JC.** Clinician beliefs and practices in dementia care: Implications for health educators. *Educational Gerontology* 2004; 30:491-516.
170. Xiong C, Miller JP, Feng G, Yan Y, Yu Q, **Morris JC.** Testing increases hazard rate for the progression time of dementia. *Discrete and Continuous Dynamical Systems Series B* 2004; 4(3):813-821.
171. Powlishta KK, Storandt M, Mandenach TA, Hogan E, Grant EA, **Morris JC.** Absence of effect of depression on cognitive performance in early stage Alzheimer's disease. *Arch Neurol* 2004; 61:1265-1268.
172. **Morris JC**, Price JL, McKeel DW, Higdon R, Buckles VD, and NNA Study Group. The neuropathology of nondemented aging. *Neurobiol Aging* 2004; 25(S2):137.
173. Shah KR, Carr D, Roe CM, Miller JP, Coats M, **Morris JC.** Impaired physical performance and the assessment of dementia of the Alzheimer type. *Alzheimer Dis Assoc Disord* 2004; 18(3):112-119.
174. Renner JA, Burns JM, Hou CE, McKeel DW, Storandt M, **Morris JC.** Progressive posterior cortical dysfunction: A clinicopathologic series. *Neurology* 2004; 63:1175-1180.
175. McKeel DW, Price JL, Miller JP, Grant EA, Xiong C, Berg L, **Morris JC.** Neuropathologic criteria for diagnosing Alzheimer Disease in persons with pure dementia of Alzheimer type J. *Neuropath and Experimental Neurol* 2004; 63(10):1028-1037.
176. Buckner RL, Head D, Parker J, Fotenos A, Marcus D, **Morris JC**, Snyder AZ. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-

based head size normalization: reliability and validation against manual measurement of total intracranial volume. *Neuroimage* 2004; 23:724-738.

177. Myers AJ, Marshall H, Holmans P, Compton D, Crook RJP, Mander A, Nowotny P, Smemo S, Dunstan M, Jehu L, Wang JC, Hamshire M, **Morris JC**, Norton J, Chakraverty S, Tunstall N, Lovestone S, Petersen R, O'Donovan M, Jones L, Williams J, Owen MJ, Hardy J, and Goate A. Variation in the Urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. *Am J Med Genet* 2004 Jan 1;124B(1)29-37.
178. Li Y, Nowotny P, Holmans P, Smemo S, Kauwe J, Hinrichs T, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Gogic G, Chan J, Cravchik A, Ross D, Lau K, Kwok S, Chang S-Y, Catanese J, Sninsky J, White T, Hardy J, Powell J, Lovestone S, **Morris JC**, Thal L, Owen M, Williams J, Goate A, Grupe A. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. *PNAS* 2004; 101(44):15688-15693.
179. Xiong C, McKeel DW, Miller JP, **Morris JC**. Combining correlated diagnostic tests: application to neuropathologic diagnosis of Alzheimer's disease. *Medical Decision Making* 2004; 24:659-669.
180. Schafer KA, Tractenberg RE, Sano M, Mackell JA, Thomas RG, Gamst A, Thal LJ, **Morris JC** for the Alzheimer's Disease Cooperative Study. Reliability of monitoring the clinical dementia rating in multicenter clinical trials. *ADAD* 2004; 18:219-222.
181. Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, **Morris JC**. Correlations between antemortem hippocampal Volume and Postmortem neuropathology in AD subjects. *ADAD* 2004; 18:190-195.
182. Brown LB, Ott BR, Papandonatos GD, Sui Y, Ready RE, **Morris JC**. Prediction of on-road driving performance in patients with early Alzheimer's disease. *J Am Geriatr Soc* 2004;53:94-98.
183. Busby V, Goossens S, Nowotny P, Hamilton G, Smemo S, Harold D, Turic D, Jehu L, Myers A, Womick M, Woo D, Compton D, Doil LM, Tacey KM, Lau KF, Al-Saraj S, Killick R, Pickering-Brown S, Moore P, Hollingworth P, Archer N, Foy C, Walter S, Lendon C, Iwatsubo T, **Morris JC**, Norton J, Mann D, Janssens B, Hardy J, O'Donovan M, Jones L, Williams J, Holmans P, Owen MJ, Grupe A, Powell J, vanHengel J, Goate A, Van Roy F, Lovestone S. α -T-Catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. *NeuroMolecular Medicine* 2004; 5:133-146.
184. Johnson J, Ostojic J, Lannfelt L, Glaser A, Basun H, Rogaeva E, Kawarai T, Bruni A, St. George Hyslop PH, Goate A, Pastor P, Chakraverty S, Norton J, **Morris JC**, Hardy J, Singleton A. No evidence for tau duplication in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found. *Neuroscience Letters* 2004; 363:99-101.
185. Li Y, Hollingworth P, Moore P, Foy C, Archer N, Powell J, Nowotny P, Holmans P, O'Donovan M, Tacey K, Doil L, vanLuchene R, Garcia V, Rowland C, Lau K, Catanese J, Sninsky J, Hardy J, Thal L, **Morris JC**, Goate A, Lovestone S, Owen M, Williams J, Grupe A. Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. *Human Mutation* 2005; 25:270-277.
186. Fotenos AF, Snyder AZ, Girton LE, **Morris JC**, and Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. *Neurology* 2005; 64:1032-1039.
187. Roe CM, Behrens MI, Xiong C, Miller JP, **Morris JC**. Alzheimer's Disease and Cancer. *Neurology* 2005; 64:895-898.

188. Kilada S, Gamaldo A, Grant EA, Moghekar A, **Morris JC**, O'Brien RJ. Brief Screening tests for the diagnosis of dementia: comparison with the Mini-Mental State Exam. *ADAD* 2005; 19:8-16.
189. Gold BT, Balota DA, Cortese MJ, Sergent-Marshall SD, Salat DH, Fischl B, Dale AM, **Morris JC**, Buckner RL. Differing neuropsychological and neuroanatomical correlates of abnormal reading in early-stage semantic dementia and dementia of the Alzheimer type. *Neuropsychologia* 2005; 43:833-846.
190. Burns JM, Galvin JE, Roe CM, **Morris JC**, McKeel DW. The pathology of the substantia Nigra in Alzheimer disease with extrapyramidal signs. *Neurology* 2005; 64:1397-1403.
191. Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, Storandt M, **Morris JC**. Predictors of preclinical Alzheimer's disease and dementia: A clinicopathologic study. *Arch Neurol* 2005; 62:758-765.
192. Head D, Synder AZ, Girton LE, **Morris JC**, Buckner RL. Frontal-hippocampal double dissociation between normal aging and Alzheimer's Disease. *Cerebral Cortex* 2005; 15:732-739.
193. Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D, Miller MK, **Morris JC**. Preclinical detection of Alzheimer's disease: Hippocampal shape and volume predict dementia onset in the elderly. *NeuroImage* 2005, 25:783-792.

Peer-Reviewed Publications (in press):

1. through 6. deleted since in press

Peer-Reviewed Publications (submitted):

1. through 25 deleted since in submission stage.

PUBLISHED ABSTRACTS

1. Grundman M, Petersen R, **Morris JC**, Ferris S, Sano M, Farlow MR, Doody R, Galasko D, Ernesto C, Thomas R, Thal L, and the ADCS Cooperative Study. Rate of dementia of Alzheimer type (DAT) in subjects with mild cognitive impairment. The Alzheimer's Disease Cooperative Study. *Neurology* 1996;46:A403.
2. Grundman M, Kim HT, **Morris JC**, Farlow MR, Heidebrink J, Hake AM, Rubin E, Ho G, Capparelli E, Schultz AN, Schafer K, Houston W, Thomas R, Thal L. A multicenter, randomized, placebo-controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (neogrofin) in mild Alzheimer's disease patients. *Society for Neuroscience* 2000;26:2046.
3. Grundman M, Capparelli E, Kim HT, **Morris JC**, Farlow MR, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ, and the Alzheimer's Disease Cooperative Study (2003): A multicenter, randomized, placebo-controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (NeotrofinTM) in mild Alzheimer's disease patients. *Life Sci* 73:539-553.
4. **Morris JC**, Price JL, McKeel DW. Neuropathology of nondemented aging (abstract), 9th World Alzheimer Congress, Philadelphia, July 2004.
5. Roe CM, Behrens MI, Xiong C, Miller JP, **Morris JC**. Dementia of the Alzheimer type and cancer. (abstract), 9th World Alzheimer Congress, Philadelphia, July 2004.

CONTRIBUTIONS TO MULTICENTER STUDIES

1. Aisen PS, Davis KL, Berg, JD, Schafer, K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ, for the Members of the Alzheimer's Disease Cooperative Study. A randomized controlled trial of Prednisone in Alzheimer's disease. *Neurology* 2000;54:588-593.
2. Mulnard RA, Cotman CW, van Dyck CH, Sano M, Doody R, Koss E, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. *JAMA* 2000;283:1007-1015.
3. Thal LJ, Calvani M, Amato A, Carta A, for the Acetyl-L-Carnitine Study Group. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. *Neurology* 2000;55:805-810.
4. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. The Members of the Alzheimer's Disease Cooperative Study, **Morris JC**. A controlled trial of Selegiline, Alpha-Tocopherol, or both as treatment for Alzheimer Disease. *N Engl J Med* 1997;336:1216-22.
5. Aisen P, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ and the Alzheimer's Disease Cooperative Study. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression. *JAMA*, June 2003; 289:2819-2826.

BOOK AND SUPPLEMENT EDITOR:

1. **Morris JC**. (Ed). Handbook of Dementing Illnesses. New York: Marcel Dekker, 1994.
2. Schneider LS, Olin JT, Doody R, Clark C, **Morris JC**, Reisberg B, Ferris SH, Schmitt F, Grundman M, Thomas R. Validity and reliability of the Alzheimer's Disease Cooperative-Clinical Global Impression of Change (ADCS-CGIC). In R. Becker and E. Giacobini (eds), *Alzheimer Disease: From Molecular Biology to Therapy*. Boston: Birkhauser, pp 425-429.
3. **Morris JC**. (Ed). Alzheimer disease and driving: Clinical, research, and public policy. *Alzheimer Disease and Associated Disorders* 11 [Suppl. 1], 1-83. 1997.
4. **Morris JC**. (Ed). Therapeutic Continuity in Alzheimer's Disease: Switching Patients to Galantamine. *Clinical Therapeutics* 23 [Suppl. A], A1-A40, 2001

REVIEWS AND EDITORIALS:

1. **Morris JC**. Relationship of plaques and tangles to Alzheimer's disease phenotype. In: Goate A, Ashall F (Eds). Pathobiology of Alzheimer's Disease. London: Academic Press, 1995, pp. 193-224.
2. **Morris JC**. Classification of dementia and Alzheimer's disease. *Acta Neurologica Scandinavica* 1996;93:41-50.
3. Hunt LA, Murphy CE, Carr D, Duchek JM, Buckles V, **Morris JC**. Environmental cueing may affect performance on a road test for drivers with dementia of the Alzheimer type. *Alzheimer Dis Assoc Disord*. 1997;11:Suppl:1:S13-S16.
4. **Morris JC**. Clinical dementia rating: A Reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *International Psychogeriatrics* 1997; 9:Suppl.1:173-176.

5. Schneider LS, Olin JT, Doody R, Clark C, **Morris JC**, Reisberg B, Schmitt F, Grundman M, Thomas R, Ferris SH. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. *Alzheimer Dis Assoc Disord*. 1997;11:Suppl. 2:S22-S32.
6. Kosik KS, Gifford DR, Greenberg SM, **Morris JC**, Sabry JH, Vickrey BG. Dementia Care. CONTINUUM 1996;2:1-203.
7. Whitehouse PJ, **Morris JC**. Disclosure of financial interest: A new policy for Alzheimer's Disease and Associated Disorders (Editorial) *Alzheimer Dis Assoc Disord* 1996; 10:1-2.
8. Friedland RP, Gilman S, **Morris JC**. Dementia in the elderly: Is it Alzheimer's? *Patient Care* 1996;18-38.
9. Carr DB, Goate A, **Morris JC**. Current concepts in the pathogenesis of Alzheimer disease. *Am J Med*. 1997;103(3A): S3-S10.
10. **Morris JC**. Alzheimer's disease: A review of clinical assessment and management issues. *Geriatrics* 1997; 52(Suppl.2):S22-S25.
11. **Morris JC**. Clinical assessment of Alzheimer's disease. *Neurology* 1997; 49 (Suppl 3):S7-S10.
12. **Morris JC**. Commentary: Recognition and initial assessment of Alzheimer's disease and related dementias. *Abstracts of Clinical Care Guidelines* 1997;9:7-8.
13. **Morris JC**. Commentary: The challenge of characterizing normal brain aging in relation to Alzheimer's disease. *Neurobiol of Aging* 1997;18:389-392.
14. **Morris JC**. Editorial: Alzheimer therapy emerges from the dark ages. *The Neurologist* 1997;3:331-332.
15. Goate AM, **Morris JC**. Commentary: Notch3 mutations and the potential for diagnostic testing for CADASIL. *Lancet* 1997;350:1490.
16. Hulette CM, Nochlin D, Sumi SM, McKeel D, **Morris JC**, Mirra SS. Letter: Clinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases. *Neurology* 1997;49:1754-1755.
17. Feldman H, Anand R, Blesa R, Duboid B, Gray J, Homma A, Mohr E, **Morris JC**, Parys W, Raschig A, Robillard A. Translation issues in clinical trials for dementia: Position paper from the international working group on harmonization of dementia drug guidelines. *Alzheimer Dis Assoc Disord*. 1997;11:Suppl. 3:61-64.
18. Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, **Morris JC**, Rogers S, and Sawada T. Clinical global measures of dementia: Position paper from the International Working Group on harmonization of dementia drug guidelines. *Alzheimer Dis Assoc Disorder*. 1997, 11:Suppl. 3:S8-S18.
19. Villareal DT, **Morris JC**. The diagnosis of Alzheimer's disease. *Alzheimer's Disease Review* 1998;3:142-152.
20. Dominguez JC, **Morris JC**. Vascular dementia and Alzheimer's disease. Making the differential diagnosis. *Alzheimer's Disease Management Today* 1999;2:3-10.
21. **Morris JC**. Lewy body variant of Alzheimer's disease. *Journal Watch Neurology* 1999;1:7,52.
22. Price JL, Phil D, Rubin EH, **Morris JC**. Revisiting Alzheimer's disease from a new perspective: Can "risk factors" play a key role. *Journal Alzheimer's of Disease* 2000;2:113-114.

23. **Morris, JC.** Foreword. Early diagnosis of Alzheimer's disease. Scinto LFM, Daffner KR (Eds). Humana Press 2000;vii-viii.
24. **Morris JC.** Alzheimer's disease: Unique, differentiable, and treatable. 52nd Annual Meeting of the American Academy of Neurology. Medscape Neurology & Neurosurgery 2000;1-14. Available at: http://www.medscape.com/Medscape/CNO/2000/AAN/pu.../Conference.cfm?conference_id=5
25. **Morris JC,** Goldman WP. Evaluating the cognitive changes of normal and pathologic aging. In: Maj M, Sartorius N (Eds) Dementia. "WPA Series Evidence and Experience in psychiatry". Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons, LTD, 2000, Vol. 3, pp. 179-182.
26. Rubin EH, Price JL, Storandt M, **Morris JC.** Pathologic-Clinical-psychometric-diagnostic relationships in individuals with and without dementia of the Alzheimer type. Research and Practice in Alzheimer's Disease. 2000 Vol. 3 pp. 19-23.
27. **Morris JC.** Is cognitive decline inevitable? Neurology Reviews Vol. 8, pp. 35-38.
28. Geula C, Farlow M, Cummings J, **Morris JC,** Scheltens P, Anand R. Alzheimer's disease: Translating neurochemical insights into clinical benefits. J Clin Psychiatry 2000;61(10)791-801.
29. Small GW, Devanand DP, Knopman DS, **Morris JC.** The evolution of Alzheimer's disease clinical criteria and therapeutic options? Med Crossfire 2001;3(2):36-44.
30. **Morris JC,** Balota DA. Editorial. Semantic dementia versus Alzheimer's disease: A matter of semantics? Neurology 2001;57:173-174.
31. **Morris JC,** Campbell KM. Review. Survey of prescribing practices for Alzheimer's disease. AAN Geriatr Neurol Newsletter Spring 2001;6-7.
32. **Morris JC.** Vitamin E in the treatment of Alzheimer's disease. Alzheimer's disease national website, 2001: <http://www.alz.org> (in press).
33. DeKosky, S, McConnell S, Branche C, Fisher W, Khachaturian Z, **Morris JC,** Petersen R, Post S, Radebaugh T, Raia P, Stone CD, Teng E, Thies W, Troxel D, Valle R, Wright L. Guidelines for the development of community-based screening programs for cognitive impairment in old people. Alzheimer Insights 2001;7(2):6-8.
34. Dobbs BM, Carr DB, **Morris JC.** Evaluation and management of the driver with dementia. Neurologist 2002;8:61-70.
35. Galvin JE, **Morris JC.** Alzheimer's disease and other dementias. 53rd Annual Meeting of the American Academy of Neurology. Medscape Neurology & Neurosurgery 2001;1-9. Available at: <http://www.medscape.com/Medscape/CNO/2001/AAN/AAN-01.html>
36. **Morris JC.** (Editorial) A change at the top of the masthead. Alzheimer Dis Assoc Disord 2001;15(3):117.
37. **Morris JC.** (Editorial) Challenging assumptions in Alzheimer disease: mild cognitive impairment and the cholinergic hypothesis. Annals of Neurology 2002;51(2):143-144.
38. Galvin JE, Palmer JL, **Morris JC.** Mild cognitive impairment represents early Alzheimer's Disease. In: Vellas B, Fitten LJ, Winbald B, Feldman H, Grundman M, Giacobini E, Kurz A. (Eds) Research and practice in Alzheimer's Disease (Volume 6). New York: Springer Publishing Company, 2002, pp. 38-42.

39. Petersen RC, **Morris JC**. A window of opportunity opens when Alzheimer's Disease is detected in its earliest stages. *Neurology Reviews* 2002; 10 (9).
40. **Morris JC**, Burns J. First U.S. Trial of Memantine for Moderate-to-Severe AD. *Journal Watch Neurology* 2003; 5(8): 61.
41. Price JL and **Morris JC**. So what if tangles precede plaques? Commentary on Schoenhet B, Zarski and Ohm TG. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. *Neurobiol of Aging* 2003 (in press).
42. Burns JM, **Morris JC**. Hypotension and dementia risk in the elderly *Journal Watch Neurology* 2004(May); Vol 6(5):37.
43. **Morris JC**. Conference Proceedings, Antecedent Biomarkers in Alzheimer's Disease II: Uses, Limitations, and Future Directions for Research. *Altered Biomarkers Conference, Alzheimer Research Forum, Philadelphia July 2004*. Available at: www.alzforum.org/res/enab/workshops/biomarkers2.asp.
44. **Morris JC**. Targeting MCI: the benefits of early intervention. *Practical Neurology* 2004 (September); Vol 3(9)24-29.

BOOK CHAPTERS

1. **Morris JC**, Ferrendelli JA. Metabolic encephalopathy. In: Pearlman AL, Collins RC (Eds) Neurological Pathophysiology (Third edition). New York: Oxford University Press, 1984, pp. 303-326.
2. **Morris JC**, Victor M. Alcohol withdrawal seizures. In: Henry G (Ed) Neurologic Emergencies. Emergency Medicine Clinics of North America. Philadelphia: W.B. Saunders Co., 1987, Vol. 5, pp. 827-839.
3. Berg L, **Morris JC**. Clinical aspects of Alzheimer's disease. In: Current Opinion in Neurology and Neurosurgery, 1989, pp. 445-450.
4. **Morris JC**, Ferrendelli JA. Metabolic encephalopathy. In: Pearlman AL, Collins RC (Eds) The Neurobiology of Disease, New York: Oxford University Press, 1989, pp. 356-379.
5. Berg L, **Morris JC**. Aging and dementia. In: Pearlman AL, Collins RC (Eds) The Neurobiology of Disease, New York: Oxford University Press, 1989, pp. 299-322.
6. **Morris JC**. Spine disease. In: Hazzard WR, Andres R, Bierman EL, Blass JP (Eds) Principles of Geriatric Medicine and Gerontology (Second edition). New York: McGraw-Hill, 1990, pp. 970-976.
7. Storandt M, **Morris JC**, Rubin EH, Coben LA, Berg L. Progression of senile dementia of the Alzheimer type on a battery of psychometric tests. In: Backman L (Ed) Memory Functions in Dementia. Amsterdam: Elsevier Science Publishers 1992, pp. 207-226.
8. **Morris JC**, Rubin EH. Clinical diagnosis and course of Alzheimer's disease. In: Davidson M (Ed) Psychiatric Clinics of North America. Philadelphia: WB Saunders Co, 1991, pp. 223-236.
9. Berg L, **Morris JC**. Diagnosis. In: Terry RB, Katzman R, Bick K (Eds) Alzheimer's Disease. New York: Raven Press, 1994, pp 9-25.
10. **Morris JC**. Evaluation of the demented patient. In: **Morris JC** (Ed) Handbook of Dementing Illnesses. New York: Marcel Dekker, 1994, pp. 71-87.

11. Renner JA, **Morris JC**. Alcohol-associated dementia. In: **Morris JC** (Ed) Handbook of Dementing Illnesses. New York: Marcel Dekker, 1994, pp. 393-412.
12. **Morris JC**. Differential diagnosis of Alzheimer's disease. In: Friedland RP (Ed) Clinics in Geriatric Medicine. Philadelphia: WB Saunders Co., 1994, pp. 257-276.
13. **Morris JC**, Storandt M, Rubin EH, McKeel DW, Price JL, Berg L. Clinical detection of very mild Alzheimer's disease. In: Bergener M, Finkel SI (Eds) Treating Alzheimer's and Other Dementias. New York: Springer Publishers, 1995, pp. 218-226.
14. **Morris JC**, Berg L, Coben LA, Rubin EH, Deuel R, Wittenborn R, Coats M, Leon S, Norton J. Clinical Dementia Rating (CDR). In: Bergener M, Finkel SI (Eds). Treating Alzheimer's and Other Dementias. New York: Springer Publishers, 1995, pp. 338-346.
15. Rockwood K, **Morris JC**. Global staging measures in dementia. In: Gauthier S (Ed). Clinical management and diagnosis of Alzheimer's disease. London: Martin Dunitz, Ltd. 1996, pp. 141-153.
16. **Morris JC**. Dementia. In: Bone RC. (Ed) Current Practice of Medicine: New York, Churchill Livingston, Inc. Current Medicine 1996, pp.3.1-3.10.
17. **Morris JC**. Diagnosis of Alzheimer Disease. In: Khachaturian ZS, Radebaugh TS (Eds). Alzheimer's disease Cause(s), Diagnosis, Treatment, and Care. CRC Press 1996, pp.76-84.
18. **Morris JC**. Clinical and neuropathological findings from CERAD. In: Becker R, Giacobini E, (Eds) Alzheimer Disease From Molecular Biology to Therapy Boston Birkhauser 1996, pp. 7-11.
19. Schneider LS, Olin JT, Doody RS, Clark CM, **Morris JC**, Reisberg B, Ferris SH, Schmitt FA, Grundman M, and Thomas RG. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). In: Becker R, Giacobini E, (Eds) Alzheimer Disease From Molecular Biology to Therapy Boston Birkhauser 1996, pp. 425-429.
20. Lindesay J, **Morris JC**. Introduction. In: Wilcock GK, Buchs RS, Rockwood (Eds). Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. Oxford: Oxford University Press 1998, pp.1-9.
21. Choi JY, **Morris JC**, Hsu CY. Aging and cerebrovascular disease. In: Neurologic Clinics. USA, W.B. Saunders Company 1998, 16:3:687-711.
22. **Morris JC**. Dementia. In: Fitzgerald F. (Ed). Current Practice of Medicine (2nd ed). Philadelphia: Current Medicine, Inc. 1999, 2(5):679-689.
23. Sahadevan S, Rockwood K, **Morris JC**. Global assessment measures in dementia. In: Gauthier SE (Ed). Clinical Diagnosis and Management of Alzheimer Disease. Martin Dunitz Ltd. London 1999, pp.167-177.
24. **Morris JC**. Clinical presentation and course of Alzheimer's disease. In: Terry RD, and Katzman R, Bick KL, Sisodia SS, (Eds). Alzheimer's Disease (2nd ed). Philadelphia, PA.: Lippincott Williams Wilkins, 1999, pp.1-24.
25. **Morris JC**. Frontotemporal dementias. In: Clark CM, Trojanowski, JQ. (Eds). Neurodegenerative Dementias. New York, NY: McGraw-Hill 2000, pp. 279-290.
26. **Morris JC**. Nosology of dementia. In: DeKosky ST (Ed). Neurologic Clinics. Philadelphia, PA: W.B. Saunders Company. Neurol Clin 2000, Vol. 18, pp. 773-788.

27. Buckles VD, Coats M, **Morris JC**. Dementia. In: Best Practice of Medicine, New York, NY: Praxis Press, Inc., 2000, pp. 1-34. Available at: <http://praxis.md/>, specialty Neurology.
28. Galvin JE, Palmer JL, **Morris JC**. Mild cognitive impairment represents early Alzheimer's disease. In: Vellas B, Grundman, Feldman H. Fitten LJ, Winbald B, Giacobini E. (Eds). Research and Practice in Alzheimer's Disease. 2001, Vol. 4.
29. Mohs RC, Doody RS, **Morris JC**, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. The preservation of function in Alzheimer's disease: results from a 1-year placebo-controlled study with donepezil. In: Vellas B, Grundman, Feldman H. Fitten LJ, Winbald B, Giacobini E. (Eds). Research and Practice in Alzheimer's Disease, 2002.
30. Petersen RC, **Morris JC**. Clinical Features. In: Peterson RC. (Eds). Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York, New York: Oxford University Press, 2003, pp. 15-39.
31. Cacchione PZ, Powlishta KK, Grant EA, Buckles VD, **Morris JC**. Collateral source reports in very mild to mild dementia of the Alzheimer type. In: Vellas B, Fitten LJ, Winblad B, Feldman H, Grundman M, Giacobini E, Kurz A. (Eds) Research and Practice in Alzheimer Disease (vol 9). Paris France: Serdi publishers, 2004, pp. 13-20.
32. Burns JM, Morris JC. Diagnosis and management of mild cognitive impairment. In: Cognitive Impairment, 2004.

LETTERS: specialty Neurology,

1. **Morris JC**, Dodson WE, Hatlelid JM, Ferrendelli JA. Phenytoin and carbamazepine (reply). *Neurology*, 38:171, 1988.
2. **Morris JC**. Dementia of the frontal lobe type. *J Neurol Neurosurg Psychiatry*, 52:145-146, 1989.
3. **Morris JC**. Aging and Alzheimer's disease (reply). *Neurology*, 41:1853, 1991.
4. **Morris JC**. Clinical Dementia Rating (reply). *Neurology*, 44:1983-1984, 1994.
5. Hulette CM, Heyman A, Nochlin D, Sumi SM, **Morris JC**, McKeel D, Mirra SS. Clinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases (reply). *Neurology*, 49:1754-1755, 1997.
6. McKeel DW, Masliah E, Hansen LA, **Morris JC**, Synaptic pathology in prefrontal cortex is present only with severe dementia. (reply) *JNEN*, 61:295-296, 2002.
7. **Morris JC**, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Reply to "Does mild cognitive impairment represent early-stage Alzheimer Disease? *Arch Neurol* 2001; 58:1705-1706.
8. Lim W-S, Liscic R, Xiong C, **Morris JC**. High dose vitamin E supplementation: time to return to the drawing board...A reply to Meta-Analysis: High-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2004.

COMMENTARIES

- Morris J.** Commentary: Revise mechanism for Alzheimer's Drug? Acetylcholine increased in earliest stage of disease. *Alzheimer Research Forum* 1/31/02

Morris J. Commentary: The quality-of-life balance: Anticholinergics in the hot seat. Alzheimer Research Forum 12/12/03

TRAINING VIDEOTAPES

1. Brief Training and Reliability Protocol for the Clinical Dementia Rating (videotapes for staging dementia severity; available in English and Japanese).
2. Non-Alzheimer Dementias (5 videotapes illustrating differential diagnosis of dementia).